Burning Rock Biotech Ltd. ( (BNR) ) has released its Q3 earnings. Here is a breakdown of the information Burning Rock Biotech Ltd. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Burning Rock Biotech Limited is a company specializing in next-generation sequencing technology for precision oncology, focusing on therapy selection testing for late-stage cancer patients and early cancer detection. In its third-quarter 2025 financial report, Burning Rock Biotech reported a total revenue of RMB131.6 million, marking a 2.3% increase compared to the same period in 2024. The company highlighted significant progress in its therapy selection and early detection studies, as well as receiving approval for its OncoGuide™ OncoScreen™ Plus CDx System in Japan.
The company’s financial performance showed mixed results, with a notable 68.6% increase in revenue from pharma research and development services, reaching RMB42.0 million. However, revenues from in-hospital and central laboratory businesses saw declines of 17.1% and 7.9%, respectively. Despite these challenges, the company achieved a gross profit of RMB98.8 million, a 7.6% increase from the previous year, with a gross margin improvement to 75.1%.
Operating expenses decreased by 11.9% to RMB115.0 million, driven by reductions in share-based compensation, budget control measures, and headcount reduction. Research and development expenses also saw a decrease of 15.6%, reflecting a strategic shift in expenditure. The net loss for the quarter was RMB16.8 million, a significant improvement from the RMB35.7 million loss in the same period of 2024.
Looking ahead, Burning Rock Biotech remains focused on enhancing its precision oncology offerings and expanding its market presence. The company continues to invest in research and development while optimizing operational efficiencies to improve its financial performance in the future.